Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers
Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers: A Cross-Sectional Observational Study
調査の概要
状態
状態
条件
条件
詳細な説明
Hemophilia is an inherited bleeding disorder caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), resulting in recurrent bleeding episodes. Repeated musculoskeletal bleeding, particularly hemarthrosis, may lead to progressive joint damage, reduced physical activity, muscle weakness, and impaired functional performance. Therefore, objective assessment of physical function is important for monitoring functional limitations and planning appropriate rehabilitation strategies in individuals with hemophilia.
The 30-Second Sit-to-Stand Test (30STS) is a simple, practical, and reliable performance-based assessment used to evaluate lower extremity strength, endurance, and functional mobility. Although the test is widely used in different populations, evidence regarding 30STS performance in individuals with hemophilia is limited. Comparing functional performance between individuals with hemophilia and healthy peers may provide valuable information regarding the functional impact of hemophilia and may contribute to clinical assessment approaches.
The aim of this cross-sectional observational study is to compare 30STS performance between individuals with hemophilia and age-matched healthy controls. Additionally, the study aims to investigate the relationship between 30STS performance, joint health status, and activity level in individuals with hemophilia.
A total of 58 participants aged 18-35 years will be included in the study, consisting of 29 individuals diagnosed with hemophilia A or hemophilia B and 29 age-matched healthy controls. All participants will perform the 30STS. Demographic characteristics, including age, height, and body weight, will be recorded. For participants with hemophilia, additional clinical information including hemophilia type, disease severity, bleeding history, and prophylaxis status will be collected.
Joint health status of individuals with hemophilia will be evaluated using the Hemophilia Joint Health Score (HJHS), and functional activity level will be assessed using the Hemophilia Activities List (HAL). The results of the 30STS will be compared between groups, and associations between functional performance, joint health, and activity level will be analyzed within the hemophilia group.
The findings of this study may contribute to a better understanding of lower extremity functional performance in individuals with hemophilia and may provide clinically relevant information for functional evaluation and rehabilitation planning
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Tuğçe Poyraz İşleyen
- 電話番号:+905354467305
- メール:tugce.poyrazisleyen@bau.edu.tr
研究場所
-
-
Istanbul
-
Istanbul、Istanbul、トルコ(Türkiye)、34353
- Bahçeşehir University
-
コンタクト:
- tuğçe Poyraz İşleyen
- 電話番号:+90(212) 381 00 00
- メール:tugce.poyrazisleyen@bau.edu.tr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Hemophilia Group:
- Diagnosis of hemophilia A or hemophilia B
- Age between 18 and 35 years
- Ability to walk independently
- Willingness to participate in the study voluntarily
Healthy Control Group:
- Age between 18 and 35 years
- No history of hemophilia or other bleeding disorders
- No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
- No neurological, rheumatological, or severe orthopedic disorders
- Willingness to participate in the study voluntarily
Exclusion Criteria:
Hemophilia Group:
- Acute joint bleeding episode within the previous 3 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Hemophilia Group
Participants aged 18-35 years with a diagnosis of hemophilia A or hemophilia B.
|
|
Healthy Control Group
Age-matched healthy participants without hemophilia or other bleeding disorders.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
30-Second Sit-to-Stand Test Performance
時間枠:Baseline assessment (single assessment visit)
|
The primary outcome of this study is the performance on the 30-Second Sit-to-Stand Test (30STS).
The test evaluates lower extremity functional performance by recording the number of correctly completed sit-to-stand repetitions within 30 seconds.
The test will be performed once under standardized conditions in both the hemophilia group and healthy control group.
Number of complete sit-to-stand repetitions performed from a standard chair within 30 seconds.
Scores range from 0 to no fixed maximum, with higher scores indicating better lower extremity functional performance and muscle endurance.
|
Baseline assessment (single assessment visit)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Joint Health Status Assessed by Hemophilia Joint Health Score (HJHS)
時間枠:Baseline assessment (single assessment visit)
|
Joint health status will be assessed in participants with hemophilia using the Hemophilia Joint Health Score (HJHS).
The HJHS evaluates hemophilic arthropathy-related findings including swelling, muscle atrophy, crepitus, range of motion loss, and pain in target joints.
Total HJHS score ranges from 0 to 124; lower scores indicate better joint health and higher scores indicate greater joint impairment.
|
Baseline assessment (single assessment visit)
|
|
Hemophilia Activities List (HAL)
時間枠:Baseline assessment (single assessment visit)
|
Functional activity level in participants with hemophilia will be assessed using the Hemophilia Activities List (HAL), a patient-reported outcome measure evaluating limitations in daily activities and participation.
The total score ranges from 0 to 100, with higher scores indicating better functional ability and fewer activity limitations.
|
Baseline assessment (single assessment visit)
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Tığçe Poyraz İşleyen、Bahçeşehir University
出版物と役立つリンク
一般刊行物
- van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, de Kleijn P, van den Berg HM, Helders PJ. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia. 2004 Sep;10(5):565-71. doi: 10.1111/j.1365-2516.2004.01016.x.
- Kuijlaars IAR, van der Net J, Feldman BM, Aspdahl M, Bladen M, de Boer W, Cuesta-Barriuso R, Matlary RED, Funk SM, Hilliard P, John JA, Kempton CL, de Kleijn P, Manco-Johnson M, Petrini P, Poonnoose P, St-Louis J, Thomas S, Timmer MA, Trakymiene SS, van Vlimmeren L, Fischer K. Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia. 2020 Nov;26(6):1072-1080. doi: 10.1111/hae.14180. Epub 2020 Oct 15.
- McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J; 1000 Norms Project Consortium. Reference values for developing responsive functional outcome measures across the lifespan. Neurology. 2017 Apr 18;88(16):1512-1519. doi: 10.1212/WNL.0000000000003847. Epub 2017 Mar 22.
- Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020 Mar;105(3):545-553. doi: 10.3324/haematol.2019.232132. Epub 2020 Feb 14.
- Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia. 2012 May;18(3):e91-4. doi: 10.1111/j.1365-2516.2011.02588.x. Epub 2011 Jun 7.
- Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost. 2003 Jul;1(7):1349-55. doi: 10.1046/j.1538-7836.2003.00262.x.
- Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia. 2012 Jul;18 Suppl 4:148-53. doi: 10.1111/j.1365-2516.2012.02841.x.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- E-78097791-020-5767
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。